Daniela De Angelis
Daniela De Angelis
Programme Leader, Medical Research Council Biostatistics Unit, Cambridge
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study
T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ...
The Lancet 399 (10332), 1303-1312, 2022
Isaac Newton Institute IID collaboration (2015) Modelling infectious disease dynamics in the complex landscape of global health
H Heesterbeek, RM Anderson, V Andreasen, S Bansal, D De Angelis, ...
Science 347, 6227, 0
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ...
The Lancet Infectious Diseases 22 (1), 35-42, 2022
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence
KME Turner, S Hutchinson, P Vickerman, V Hope, N Craine, N Palmateer, ...
Addiction 106 (11), 1978-1988, 2011
The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis
AM Presanis, D De Angelis, ...
PLoS medicine 6 (12), e1000207, 2009
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment
J Kimber, L Copeland, M Hickman, J Macleod, J McKenzie, D De Angelis, ...
Bmj 341, 2010
Modeling the percolation of annotation errors in a database of protein sequences
WR Gilks, B Audit, D De Angelis, S Tsoka, CA Ouzounis
Bioinformatics 18 (12), 1641-1649, 2002
A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales
OO Aalen, VT Farewell, D de Angelis, NE Day, O Nöel Gill
Statistics in medicine 16 (19), 2191-2210, 1997
Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model
MJ Price, AE Ades, D De Angelis, NJ Welton, J Macleod, K Soldan, ...
American journal of epidemiology 178 (3), 484-492, 2013
HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study
PJ Birrell, ON Gill, VC Delpech, AE Brown, S Desai, TR Chadborn, ...
The Lancet infectious diseases 13 (4), 313-318, 2013
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS …
A Babiker, S Darby, D De Angelis, D Kwart, K Porter, V Beral, ...
Lancet 355 (9210), 2000
Bayesian modeling to unmask and predict influenza A/H1N1pdm dynamics in London
PJ Birrell, G Ketsetzis, NJ Gay, BS Cooper, AM Presanis, RJ Harris, ...
Proceedings of the National Academy of Sciences 108 (45), 18238-18243, 2011
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact
NK Martin, GR Foster, J Vilar, S Ryder, M E Cramp, F Gordon, JF Dillon, ...
Journal of viral hepatitis 22 (4), 399-408, 2015
Risk of hospital admission for patients with SARS-CoV-2 variant B. 1.1. 7: cohort analysis
T Nyberg, KA Twohig, RJ Harris, SR Seaman, J Flannagan, H Allen, ...
bmj 373, 2021
Estimating HIV incidence, time to diagnosis, and the undiagnosed HIV epidemic using routine surveillance data
A van Sighem, F Nakagawa, D De Angelis, C Quinten, D Bezemer, ...
Epidemiology (Cambridge, Mass.) 26 (5), 653, 2015
Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England
A Nicoll, G Hughes, M Donnelly, S Livingstone, D De Angelis, K Fenton, ...
Sexually Transmitted Infections 77 (4), 242-247, 2001
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
RJ Harris, M Ramsay, VD Hope, L Brant, M Hickman, GR Foster, ...
The European Journal of Public Health 22 (2), 187-192, 2012
Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under …
RJ Harris, B Thomas, J Griffiths, A Costella, R Chapman, M Ramsay, ...
Journal of hepatology 61 (3), 530-537, 2014
HCV Treatment as Prevention in People Who Inject Drugs–testing the evidence
M Hickman, D De Angelis, P Vickerman, S Hutchinson, N Martin
Current opinion in infectious diseases 28 (6), 576, 2015
Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths
D De Angelis, M Hickman, S Yang
American Journal of Epidemiology 160 (10), 994-1004, 2004
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20